Topic Hub
15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 15 of 15 clinical reviews.
Saxenda (liraglutide 3 mg) is being studied off-label for alcohol use disorder. Learn what the current clinical evidence shows, how GLP-1 receptors affect alcohol craving, what monitoring is required, and how this compares to FDA-approved AUD treatments.
Read clinical reviewCan liraglutide 3 mg (Saxenda) treat alcohol use disorder? We review the preclinical and early clinical evidence, FDA-approved indications, risks, and what patients should know about this off-label use.
Read clinical reviewA clinician-reviewed guide to the off-label use of Saxenda (liraglutide 3 mg) for alcohol use disorder, covering the current evidence base, GRADE rating, proposed dosing protocols, risks, and how it compares to FDA-approved treatments.
Read clinical reviewLiraglutide 3 mg (Saxenda) is being studied off-label for alcohol use disorder. This evidence summary covers preclinical data, early clinical trials, mechanism of action, and what clinicians should know.
Read clinical reviewCan liraglutide 3 mg (Saxenda) treat binge eating disorder? Review of clinical trials, dosing, off-label evidence, and what the research actually shows about GLP-1 receptor agonists for BED.
Read clinical reviewLiraglutide 3 mg (Saxenda) is used off-label for binge eating disorder. Review the clinical evidence, required monitoring labs, safety signals, and how prescribers manage BED patients on GLP-1 therapy.
Read clinical reviewLiraglutide 3 mg (Saxenda) is sometimes used off-label for binge eating disorder. This article reviews the evidence, dosing protocol, safety considerations, and how it compares to FDA-approved BED treatments.
Read clinical reviewCan Saxenda (liraglutide 3 mg) treat binge eating disorder? Review the off-label evidence, clinical trial data, risks, and how GLP-1 receptor agonists affect binge eating behavior.
Read clinical reviewLiraglutide 3 mg (Saxenda) is used off-label for NASH. Review the dosing protocol, LEAN trial evidence, histological outcomes, and practical clinical considerations.
Read clinical reviewA clinical evidence summary of liraglutide 3 mg (Saxenda) used off-label for nonalcoholic steatohepatitis (NASH), covering trial data, mechanisms, dosing, and guideline positions.
Read clinical reviewLiraglutide 3 mg (Saxenda) is used off-label for nonalcoholic steatohepatitis (NASH). Review the clinical trial data, monitoring protocols, liver enzyme tracking, and imaging benchmarks that guide safe prescribing.
Read clinical reviewA clinical evidence summary of Saxenda (liraglutide 3 mg) used off-label for polycystic ovary syndrome (PCOS), covering trial data, hormonal outcomes, weight effects, and prescribing considerations.
Read clinical reviewA clinical review of liraglutide 3 mg (Saxenda) used off-label for polycystic ovary syndrome (PCOS), covering trial data, metabolic and reproductive outcomes, side effects, and when prescribers consider it.
Read clinical reviewA clinical review of liraglutide 3 mg (Saxenda) used off-label for polycystic ovary syndrome (PCOS): evidence grading, dosing protocols, expected outcomes, and who may benefit most.
Read clinical reviewLiraglutide 3 mg (Saxenda) is used off-label for polycystic ovary syndrome (PCOS). Learn the evidence, monitoring protocols, and what clinicians track during treatment.
Read clinical review